BR112023020233A2 - Terapia de combinação para tratamento de câncer - Google Patents

Terapia de combinação para tratamento de câncer

Info

Publication number
BR112023020233A2
BR112023020233A2 BR112023020233A BR112023020233A BR112023020233A2 BR 112023020233 A2 BR112023020233 A2 BR 112023020233A2 BR 112023020233 A BR112023020233 A BR 112023020233A BR 112023020233 A BR112023020233 A BR 112023020233A BR 112023020233 A2 BR112023020233 A2 BR 112023020233A2
Authority
BR
Brazil
Prior art keywords
combination therapy
cancer treatment
cancer
mutant
egfr
Prior art date
Application number
BR112023020233A
Other languages
English (en)
Inventor
K Nyati Mukesh
Kumar Mehta Ranjit
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of BR112023020233A2 publication Critical patent/BR112023020233A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

terapia de combinação para tratamento de câncer. são fornecidos no presente documento métodos de tratamento de um câncer que compreendem administrar um degradador de egfr a um paciente que sofre do mesmo e submeter o paciente à radiação. o câncer pode expressar egfr mutante, kras mutante ou braf mutante superexpresso ou excessivamente ativado.
BR112023020233A 2021-04-02 2022-04-01 Terapia de combinação para tratamento de câncer BR112023020233A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163170038P 2021-04-02 2021-04-02
PCT/US2022/022990 WO2022212806A1 (en) 2021-04-02 2022-04-01 Combination therapy for cancer treatment

Publications (1)

Publication Number Publication Date
BR112023020233A2 true BR112023020233A2 (pt) 2023-12-19

Family

ID=83459862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020233A BR112023020233A2 (pt) 2021-04-02 2022-04-01 Terapia de combinação para tratamento de câncer

Country Status (10)

Country Link
US (1) US20240197711A1 (pt)
EP (1) EP4313029A1 (pt)
JP (1) JP2024512743A (pt)
KR (1) KR20240016250A (pt)
CN (1) CN117337175A (pt)
AU (1) AU2022246670A1 (pt)
BR (1) BR112023020233A2 (pt)
CA (1) CA3214172A1 (pt)
MX (1) MX2023011597A (pt)
WO (1) WO2022212806A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029502B2 (en) * 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
AU2017254713C1 (en) * 2016-04-22 2021-04-29 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of EGFR and methods of use
US20190091229A1 (en) * 2017-09-27 2019-03-28 Lam Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors
EP3755697A4 (en) * 2018-02-20 2021-10-27 Dana-Farber Cancer Institute, Inc. EGFR DEGRADER AND METHOD OF USE THEREOF
CN116997551A (zh) * 2020-10-12 2023-11-03 密歇根大学董事会 Egfr调节剂的合成

Also Published As

Publication number Publication date
US20240197711A1 (en) 2024-06-20
CN117337175A (zh) 2024-01-02
MX2023011597A (es) 2023-10-30
WO2022212806A1 (en) 2022-10-06
JP2024512743A (ja) 2024-03-19
KR20240016250A (ko) 2024-02-06
AU2022246670A1 (en) 2023-10-26
EP4313029A1 (en) 2024-02-07
CA3214172A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
BR112019021822A2 (pt) Terapia de combinação
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
BR112018007447A2 (pt) terapia de combinação para tratamento de malignidades
EA202092154A1 (ru) Комбинированная терапия
BR112018007656A2 (pt) terapia de combinação para tratamento de doenças malignas
NO20066054L (no) behandling med cisplatin og en EGFR-inhibitor
BR112018074981A2 (pt) tratamentos de câncer
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
MX2021007554A (es) Terapia de combinacion para el tratamiento de cancer.
BR112019011350A2 (pt) terapia de combinação
BR112021020601A2 (pt) Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2021003262A (es) Metodos de tratamiento.
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
BR112023020233A2 (pt) Terapia de combinação para tratamento de câncer
BR112021016923A2 (pt) Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
MX2021003265A (es) Metodos de tratamiento.